Lucid Diagnostics Inc (LUCD) is now in the Overvalued zone, suggesting that its current forward PS ratio of 19.02 is considered Overvalued compared with the five-year average of -2.09. The fair price of Lucid Diagnostics Inc (LUCD) is between 0.94 to 1.28 according to relative valuation method. Compared to the current price of 1.45 USD , Lucid Diagnostics Inc By Overvalued By 13.22%.

Relative Value

Fair Zone

0.94-1.28

Current Price：1.45

13.22%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Lucid Diagnostics Inc (LUCD) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Lucid Diagnostics Inc (LUCD) has a current Price-to-Book (P/B) ratio of -4.90. Compared to its 3-year average P/B ratio of 2.49, the current P/B ratio is approximately -296.53% higher. Relative to its 5-year average P/B ratio of 2.05, the current P/B ratio is about -338.86% higher. Lucid Diagnostics Inc (LUCD) has a Forward Free Cash Flow (FCF) yield of approximately -28.65%. Compared to its 3-year average FCF yield of -59.03%, the current FCF yield is approximately -51.47% lower. Relative to its 5-year average FCF yield of -49.80%, the current FCF yield is about -42.46% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LUCD competitors is 5.10, providing a benchmark for relative valuation. Lucid Diagnostics Inc Corp (LUCD.O) exhibits a P/S ratio of 19.02, which is 272.68% above the industry average. Given its robust revenue growth of 3.33%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LUCD increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LUCD in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LUCD currently overvalued or undervalued?

What is Lucid Diagnostics Inc (LUCD) fair value?

LUCD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Lucid Diagnostics Inc (LUCD) is between 0.94 to 1.28 according to relative valuation method.

How does LUCD's valuation metrics compare to the industry average?

The average P/S ratio for LUCD's competitors is 5.10, providing a benchmark for relative valuation. Lucid Diagnostics Inc Corp (LUCD) exhibits a P/S ratio of 19.02, which is 272.68% above the industry average. Given its robust revenue growth of 3.33%, this premium appears unsustainable.

What is the current P/B ratio for Lucid Diagnostics Inc (LUCD) as of Mar 03 2026?

As of Mar 03 2026, Lucid Diagnostics Inc (LUCD) has a P/B ratio of -4.90. This indicates that the market values LUCD at -4.90 times its book value.

What is the current FCF Yield for Lucid Diagnostics Inc (LUCD) as of Mar 03 2026?

As of Mar 03 2026, Lucid Diagnostics Inc (LUCD) has a FCF Yield of -28.65%. This means that for every dollar of Lucid Diagnostics Inc's market capitalization, the company generates -28.65 cents in free cash flow.

What is the current Forward P/E ratio for Lucid Diagnostics Inc (LUCD) as of Mar 03 2026?

As of Mar 03 2026, Lucid Diagnostics Inc (LUCD) has a Forward P/E ratio of -3.09. This means the market is willing to pay $-3.09 for every dollar of Lucid Diagnostics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Lucid Diagnostics Inc (LUCD) as of Mar 03 2026?

As of Mar 03 2026, Lucid Diagnostics Inc (LUCD) has a Forward P/S ratio of 19.02. This means the market is valuing LUCD at $19.02 for every dollar of expected revenue over the next 12 months.

LUCD Valuation